European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society (Q38039480)

From Wikidata

Jump to navigation Jump to search

scientific article published on 03 September 2012

Language	Label	Description	Also known as
English	European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society	scientific article published on 03 September 2012

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society (English)

1 reference

Europe PubMed Central

27 August 2017

gabapentin enacarbil

1 reference

ChEBI release 2020-05-28

restless legs syndrome

1 reference

based on heuristic

inferred from title

Poul Jørgen Jennum

8

1 reference

Europe PubMed Central

27 August 2017

Markku Partinen

9

1 reference

Europe PubMed Central

27 August 2017

Claudia Trenkwalder

5

object named as

Claudia Trenkwalder

1 reference

Europe PubMed Central

27 August 2017

Shaun T O'Keeffe

object named as

Shaun O'Keeffe

4

0 references

object named as

Karel Sonka

14

0 references

6

object named as

Birgit Högl

1 reference

Europe PubMed Central

27 August 2017

Luigi Ferini Strambi

2

object named as

Luigi Ferini-Strambi

1 reference

Europe PubMed Central

27 August 2017

European Federation of Neurological Societies

16

object named as

European Federation of Neurological Societies

1 reference

Europe PubMed Central

27 August 2017

author name string

Diego Garcia-Borreguero

1

1 reference

Europe PubMed Central

27 August 2017

Ralf Kohnen

3

1 reference

Europe PubMed Central

27 August 2017

Heike Benes

7

1 reference

Europe PubMed Central

27 August 2017

Danyal Fer

10

1 reference

Europe PubMed Central

27 August 2017

Pasquale Montagna

11

1 reference

Europe PubMed Central

27 August 2017

Claudio L Bassetti

12

1 reference

Europe PubMed Central

27 August 2017

Alex Iranzo

13

1 reference

Europe PubMed Central

27 August 2017

Anne-Marie Williams

15

1 reference

Europe PubMed Central

27 August 2017

European Neurological Society

17

1 reference

Europe PubMed Central

27 August 2017

European Sleep Research Society

18

1 reference

Europe PubMed Central

27 August 2017

publication date

3 September 2012

1 reference

Europe PubMed Central

27 August 2017

European Journal of Neurology

1 reference

Europe PubMed Central

27 August 2017

19

1 reference

Europe PubMed Central

27 August 2017

11

1 reference

Europe PubMed Central

27 August 2017

1385-1396

1 reference

Europe PubMed Central

27 August 2017

Ferritin subunits in CSF are decreased in restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Circadian changes in CSF dopaminergic measures in restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

The role of iron in restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Pathophysiology of restless legs syndrome: evidence for iron involvement

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

MRI measurement of brain iron in patients with restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

A genetic risk factor for periodic limb movements in sleep

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Patient- and physician-rated measures demonstrate the effectiveness of ropinirole in the treatment of restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Efficacy and safety of pramipexole in restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Long-term open-label study of pramipexole in patients with primary restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Long-term treatment with pramipexole in restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Lisuride treatment of restless legs syndrome: first studies with monotherapy in de novo patients and in combination with levodopa in advanced disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Management of restless legs syndrome by the partial D2-agonist terguride

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

A 52-week study of gabapentin enacarbil in restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Oxcarbazepine treatment of restless legs syndrome: three case reports.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Pilot trial of lamotrigine in the restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Levetiracetam can be effective in the treatment of restless legs syndrome with periodic limb movements in sleep: report of two cases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Proposed dose equivalence between clonazepam and pramipexole in patients with restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Investigating the response to intravenous iron in restless legs syndrome: an observational study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Iron deficiency with normal ferritin levels in restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Augmentation in restless legs syndrome is associated with low ferritin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Pilot trial of onabotulinumtoxina (Botox) in moderate to severe restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Bupropion and restless legs syndrome: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Comparison of two infrared devices in their effectiveness in reducing symptoms associated with RLS.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Restless legs syndrome and near-infrared light: An alternative treatment option.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Exercise and restless legs syndrome: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Intradialytic aerobic exercise training ameliorates symptoms of restless legs syndrome and improves functional capacity in patients on hemodialysis: a pilot study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Magnesium not likely to play a major role in the pathogenesis of Restless Legs Syndrome: serum and cerebrospinal fluid studies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Depression of spinal sensory transmission during REM sleep: dopaminergic involvement and insights into restless legs syndrome. Focus on "state-dependent changes in glutamate, glycine, GABA, and dopamine levels in cat lumbar spinal cord".

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Effects of pregabalin on the activity of glutamate transporter type 3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Evidence that pregabalin reduces neuropathic pain by inhibiting the spinal release of glutamate

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Effects of immobility on sensory and motor symptoms of restless legs syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Dopaminergic augmentation of restless legs syndrome: the scope of the problem.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Augmentation of restless legs syndrome with long-term tramadol treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03853.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2012.03853.X

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38039480&oldid=2108271662"